• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
NeoPharm, Inc. - Product Pipeline Review - Q4 2010 Product Image

NeoPharm, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 58 pages
  • GlobalData

NeoPharm, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “NeoPharm, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NeoPharm, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NeoPharm, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the READ MORE >



List of Tables
List of Figures
NeoPharm, Inc. Snapshot
NeoPharm, Inc. Overview
Key Information
Key Facts
NeoPharm, Inc. – Research and Development Overview
Key Therapeutic Areas
NeoPharm, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
NeoPharm, Inc. – Pipeline Products Glance
NeoPharm, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
NeoPharm, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
NeoPharm, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
NeoPharm, Inc. – Drug Profiles
Cintredekin Besudotox
Product Description
Mechanism of Action
R&D Progress
Cintredekin Besudotox
Product Description
Mechanism of Action
R&D Progress
LE-DT
Product Description
Mechanism of Action
R&D Progress
LE-SN38
Product Description
Mechanism of Action
R&D Progress
LEP -ETU
Product Description
Mechanism of Action
R&D Progress
Liposome Encapsulated Mitoxantrone (LEM)
Product Description
Mechanism of Action
R&D Progress
Liposome Entrapped Docetaxel
Product Description
Mechanism of Action
R&D Progress
Cintredekin Besudotox
Product Description
Mechanism of Action
R&D Progress
IL13-PE38QQR + Temozolomide + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
LE-SN38
Product Description
Mechanism of Action
R&D Progress
LEP -ETU
Product Description
Mechanism of Action
R&D Progress
LErafAON
Product Description
Mechanism of Action
R&D Progress
Liposome Entrapped Docetaxel
Product Description
Mechanism of Action
R&D Progress
Cintredekin Besudotox
Product Description
Mechanism of Action
R&D Progress
NeoPharm, Inc. – Pipeline Analysis
NeoPharm, Inc. – Pipeline Products by Therapeutic Class
NeoPharm, Inc. Pipeline Products By Target
NeoPharm, Inc. – Pipeline Products by Molecule Type
NeoPharm, Inc. – Recent Pipeline Updates
NeoPharm, Inc. – Company Statement
NeoPharm, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 17, 2010: NeoPharm Receives FDA Orphan Drug Designation For IL13-PE38QQR For Treatment Of Idiopathic Pulmonary Fibrosis
Apr 20, 2010: NeoPharm Initiates Patient Enrollment In Phase II Trial Of LE-DT
Mar 11, 2010: NeoPharm Files Orphan Drug Application For IL13-PE38QQR For Treatment Of IPF
Mar 11, 2010: NeoPharm Files Orphan Drug Application For IL13-PE38QQR For Treatment Of IPF
Mar 11, 2010: NeoPharm Files Orphan Drug Application For IL13-PE38QQR For Treatment Of IPF
Mar 11, 2010: NeoPharm Files Orphan Drug Application For IL13-PE38QQR For Treatment Of IPF
Jan 06, 2010: NeoPharm Announces Phase II Data Of Liposome-Entrapped Paclitaxel (LEP) For The Treatment Of Metastatic Breast Cancer
Jan 04, 2010: NeoPharm Announces IND Filing Of IL13-PE38QQR For The Treatment Of Idiopathic Pulmonary Fibrosis
Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference
Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference
Financial Deals Landscape
NeoPharm, Inc., Deals Volume Summary, 2004 to YTD 2010
NeoPharm, Inc., Deals Summary By Region, 2004 to YTD 2010
NeoPharm, Inc., Deals Summary, 2004 to YTD 2010
NeoPharm, Inc. Detailed Deal Summary
Equity Offering
NeoPharm Completes Public Offering Of $41.06 Million
NeoPharm Completes Public Offering Of $78.7 Million
NeoPharm Signs Research And Development Agreement With National Institute of Neurological Disorders and Stroke
Licensing Agreements
NeoPharm Enters Into Licensing Agreement With National Institute Of Health
NeoPharm Enters Into A Licensing Agreement With Nippon Kayaku
Nippon Kayaku Terminates Licensing Agreement With NeoPharm
NeoPharm Terminates Licensing Agreement With Pfizer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS